Quick Takeaways
- LEXX - Lexaria Bioscience Corp. has 12 insiders with reported activity on this page.
- Net insider value flow over the last year: +$49,085.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
Insider Transactions Reported by 12 Insiders of Lexaria Bioscience Corp.
- Symbol
- LEXX on Nasdaq
- Location
- Kelowna, British Columbia, Canada
What Changed
- Buy value: $49,085; sell value: $0.
- Net share flow: +53,626.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsNet insider flow leans to buying over the last 12 months. Net value: +$49,085.
Buys
$49,085
Shares: 53,626
Insiders: 5
Sells
$0
Shares: 0
Insiders: 0
Net
+$49,085
Shares: +53,626
Insiders: 5
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 53,626 | 0 | $49,085 | $0 | +$49,085 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Lexaria Bioscience Corp. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Christopher Bunka | Director | $533,006 | +$25,241 | +5% | Mixed | 17 Mar 2026 |
| Richard Christopher | Chief Executive Officer, Director | $363,611 | +$13,641 | +3.9% | Mixed | 29 Jul 2025 |
| John Martin Docherty | President & CSO, Director | $322,458 | +$4,989 | +1.6% | Mixed | 29 Jul 2025 |
| Michael Elliot Shankman | Chief Financial Officer | $122,000 | Mixed | 15 May 2025 | ||
| Nicholas W. Baxter | Director | $90,280 | Mixed | 15 May 2025 | ||
| William Edward McKechnie | Director | $71,296 | +$4,532 | +6.8% | Mixed | 29 Jul 2025 |
| Vanessa Carle | Secretary | $65,932 | +$683 | +1% | Mixed | 29 Jul 2025 |
| Albert L. Reese Jr. | Director | $65,778 | Mixed | 15 May 2025 | ||
| Baljinder Bhullar | Director | $15,860 | Mixed | 15 May 2025 | ||
| Catherine C. Turkel | Director | $9,703 | Filing P/S | 12 Aug 2024 | ||
| Gregory Downey | Chief Financial Officer | $4,084 | Filing P/S | 14 Oct 2022 | ||
| Nelson Cabatuan | Chief Financial Officer | Mixed | 14 Mar 2024 |
Top shareholders of Lexaria Bioscience Corp. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Christopher Bunka |
3/4/5
|
Director |
—
mixed-class rows
|
740,289
mixed-class rows
|
$533,006 | +$25,241 | 17 Mar 2026 | |
| Richard Christopher |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
415,000
mixed-class rows
|
$363,611 | +$13,641 | 29 Jul 2025 | |
| John Martin Docherty |
3/4/5
|
President & CSO, Director |
—
mixed-class rows
|
370,285
mixed-class rows
|
$322,458 | +$4,989 | 29 Jul 2025 | |
| Invenomic Capital Management LP |
13F
|
Company |
—
class O/S missing
|
470,915
|
$290,555 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
—
class O/S missing
|
361,300
|
$222,923 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
—
class O/S missing
|
258,816
|
$159,689 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
—
class O/S missing
|
219,718
|
$135,587 | — | 31 Dec 2025 | |
| Michael Elliot Shankman |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
100,000
|
$122,000 | — | 15 May 2025 | |
| Nicholas W. Baxter |
3/4/5
|
Director |
—
mixed-class rows
|
74,000
mixed-class rows
|
$90,280 | — | 15 May 2025 | |
| TORONTO DOMINION BANK |
13F
|
Company |
—
class O/S missing
|
140,013
|
$86,460 | — | 31 Dec 2025 | |
| William Edward McKechnie |
3/4/5
|
Director |
—
mixed-class rows
|
81,191
mixed-class rows
|
$71,296 | +$4,532 | 29 Jul 2025 | |
| Vanessa Carle |
3/4/5
|
Secretary |
—
mixed-class rows
|
75,817
mixed-class rows
|
$65,932 | +$683 | 29 Jul 2025 | |
| Albert L. Reese Jr. |
3/4/5
|
Director |
—
mixed-class rows
|
53,917
mixed-class rows
|
$65,778 | — | 15 May 2025 | |
| Byrne Asset Management LLC |
13F
|
Company |
—
class O/S missing
|
105,500
|
$65,094 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
—
class O/S missing
|
39,301
|
$24,249 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
—
class O/S missing
|
27,445
|
$16,934 | — | 31 Dec 2025 | |
| Krilogy Financial LLC |
13F
|
Company |
—
class O/S missing
|
19,653
|
$15,998 | — | 31 Dec 2025 | |
| Baljinder Bhullar |
3/4/5
|
Director |
—
mixed-class rows
|
24,000
mixed-class rows
|
$15,860 | — | 15 May 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
—
class O/S missing
|
18,389
|
$11,346 | — | 31 Dec 2025 | |
| Catherine C. Turkel |
3/4/5
|
Director |
—
mixed-class rows
|
45,100
mixed-class rows
|
$9,703 | — | 12 Aug 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
—
class O/S missing
|
15,600
|
$9,625 | — | 31 Dec 2025 | |
| BANK OF MONTREAL /CAN/ |
13F
|
Company |
—
class O/S missing
|
14,083
|
$8,689 | — | 31 Dec 2025 | |
| Gregory Downey |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
47,954
mixed-class rows
|
$4,084 | — | 14 Oct 2022 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
—
class O/S missing
|
7,283
|
$4,000 | — | 31 Dec 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
—
class O/S missing
|
2,195
|
$1,358 | — | 31 Dec 2025 | |
| Federation Des Caisses Desjardins du Quebec |
13F
|
Individual |
—
class O/S missing
|
382
|
$233 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
—
class O/S missing
|
203
|
$126 | — | 31 Dec 2025 | |
| MAI Capital Management |
13F
|
Company |
—
class O/S missing
|
200
|
$124 | — | 31 Dec 2025 | |
| Farther Finance Advisors, LLC |
13F
|
Company |
—
class O/S missing
|
166
|
$102 | — | 31 Dec 2025 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
—
class O/S missing
|
22,919
|
$96 | — | 31 Dec 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
—
class O/S missing
|
32
|
$20 | — | 31 Dec 2025 | |
| GABLES CAPITAL MANAGEMENT INC. |
13F
|
Company |
—
class O/S missing
|
13
|
$8 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
—
class O/S missing
|
3
|
$2 | — | 31 Dec 2025 | |
| Clear Street Group Inc. |
13F
|
Company |
—
class O/S missing
|
200
|
$1 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for Lexaria Bioscience Corp.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Christopher Bunka | LEXX | common shares | Gift | -26.8% | -100,000 | 273,543 | 17 Mar 2026 | Direct | ||
| Christopher Bunka | LEXX | common shares | Purchase | 4.41% | $10,866 | $0.9131 | 11,900 | 281,912 | 30 Jul 2025 | Private Holding Company |
| Christopher Bunka | LEXX | common shares | Purchase | 6.13% | $14,375 | $0.9215 | 15,600 | 270,012 | 29 Jul 2025 | Private Holding Company |
| William Edward McKechnie | LEXX | common shares | Purchase | 37.9% | $4,532 | $0.9063 | 5,000 | 18,191 | 29 Jul 2025 | Direct |
| John Martin Docherty | LEXX | common shares | Purchase | $4,989 | $0.9280 | 5,376 | 5,376 | 29 Jul 2025 | Direct | |
| Vanessa Carle | LEXX | common shares | Purchase | $682 | $0.9100 | 750 | 750 | 29 Jul 2025 | Direct | |
| Richard Christopher | LEXX | common shares | Purchase | 30% | $13,641 | $0.9094 | 15,000 | 65,000 | 29 Jul 2025 | Direct |
| Richard Christopher | LEXX | Stock Options | Award | 75% | 150,000 | 350,000 | 15 May 2025 | Direct | ||
| Christopher Bunka | LEXX | Stock Options | Award | 6.33% | 11,000 | 184,834 | 15 May 2025 | Direct | ||
| Vanessa Carle | LEXX | Stock Options | Award | 25% | 15,000 | 75,000 | 15 May 2025 | Direct | ||
| John Martin Docherty | LEXX | Stock Options | Award | 93.3% | 150,000 | 310,834 | 15 May 2025 | Direct | ||
| Michael Elliot Shankman | LEXX | Stock Options | Award | 100% | 50,000 | 100,000 | 15 May 2025 | Direct | ||
| Baljinder Bhullar | LEXX | Stock Options | Award | 11,000 | 11,000 | 15 May 2025 | Direct | |||
| Nicholas W. Baxter | LEXX | Stock Options | Award | 21.2% | 11,000 | 63,000 | 15 May 2025 | Direct | ||
| Albert L. Reese Jr. | LEXX | Stock Options | Award | 34.4% | 11,000 | 43,000 | 15 May 2025 | Direct | ||
| William Edward McKechnie | LEXX | Stock Options | Award | 21.2% | 11,000 | 63,000 | 15 May 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.